In recent years, multifaceted clinical benefits of polymeric therapeutics have been reported. Over the
past decades, cancer has been one of the leading causes of mortality in the world. Many clinically approved chemotherapeutics
encounter potential challenges against deadly cancer. Moreover, safety and efficacy of anticancer
agents have been limited by undesirable pharmacokinetics and biodistribution. To address these limitations, various
polymer drug conjugates are being studied and developed to improve the antitumor efficacy. Among other therapeutics,
polymer therapeutics are well established platforms that circumvent anticancer therapeutics from enzymatic
metabolism via direct conjugation to therapeutic molecules. Interestingly, polymer therapeutics meets an
unmet need of small molecules. Further clinical study showed that polymer-drug conjugation can achieve desired pharmacokinetics and
biodistribution properties of several anticancer drugs. The present retrospective review mainly enlightens the most recent preclinical and
clinical studies include safety, stability, pharmacokinetic behavior and distribution of polymer therapeutics.
Keywords: Biodistribution, cancer, delivery, polymer conjugation, polymer therapeutics, pharmacokinetics.
Rights & PermissionsPrintExport